PDMR Notification

MGC Pharmaceuticals Limited

28 March 2024

 

MGC Pharmaceuticals Ltd.

PDMR Notification

28 March 2024

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Persons Discharging Managerial Responsibilities (PDMR) were issued a combined 240,000 unlisted options as approved at a meeting of shareholders on 18 March 2024. This notification is made in accordance the UK Market Abuse Regulations.

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Daniel Robinson
2	Reason for the notification
(a)	Position		Non-Executive Director
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Unlisted options exercisable at A$0.42 on or before 28 March 2027.
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Grant of Options over Ordinary Shares
(d)	Currency	Price		Volume	Total
	AUD	0.00		120,000	N/A
	Aggregated information
	AUD	0.00		120,000	N/A
(e)	Date of transaction		28 March 2024
(f)	Place of transaction		Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Layton Mills
2	Reason for the notification
(a)	Position		Non-Executive Director
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Unlisted options exercisable at A$0.42 on or before 28 March 2027.
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Grant of Options over Ordinary Shares
(d)	Currency	Price		Volume	Total
	AUD	0.00		120,000	N/A
	Aggregated information
	AUD	0.00		120,000	N/A
(e)	Date of transaction		28 March 2024
(f)	Place of transaction		Outside a trading venue

-Ends-

Authorised for release by the Company Secretary, for further information please contact:

MGC Pharmaceuticals Ltd              Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd Rowan Harland Company Secretary [phone] [e-mail]
UK IR/PR Advisers  IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen [phone] [e-mail]	UK Brokers Oberon Capital Aimee McCusker / Adam Pollock [phone] [e-mail] [e-mail]

 

END